Exome Asset Management »

Autolus Therapeutics Plc spon ads shares owned by Exome Asset Management

Quarter-by-quarter ownership of Autolus Therapeutics Plc spon ads (AUTL) shares owned by Exome Asset Management from 13F filings

Historical chart of Exome Asset Management investment in Autolus Therapeutics Plc spon ads

Tip: Access up to 7 years of quarterly data

All positions including Autolus Therapeutics Plc spon ads held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Autolus Therapeutics Plc spon ads by Exome Asset Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $2.9M 840k 3.48

More positions owned by Exome Asset Management

Eli Lilly & Co. (LLY)
Ascendis Pharma A/s Sponsored Adr (ASND)
Bridgebio Pharma (BBIO)
Structure Therapeutics Sponsored Ads (GPCR)
Tg Therapeutics (TGTX)
Align Technology (ALGN)
Cigna Corp (CI)
Gilead Sciences (GILD)
Geron Corporation (GERN)
Biontech Se Sponsored Ads (BNTX)
Bristol Myers Squibb (BMY)
Miragen Therapeutics (VRDN)
Intuitive Surgical Com New (ISRG)
Beigene Sponsored Adr (BGNE)
Blueprint Medicines (BPMC)

View all positions for Exome Asset Management

Top funds holding Autolus Therapeutics Plc spon ads

Syncona Portfolio
Blackstone Group
Deep Track Capital
Polygon Management
Armistice Capital
Frazier Life Sciences Management
Affinity Asset Advisors
BlackRock
BlackRock
T. Rowe Price Associates
Deerfield Management Company
Laurion Capital Management
Morgan Stanley
Dr. Jeffrey R. Jay, M.D.
Stempoint Capital

View all funds holding Autolus Therapeutics Plc spon ads